Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

Overview of attention for article published in BMC Cancer, July 2014

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 45 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 33 publications that cite this research output.

33

The most recent citing publications are shown below. View all 33 publications that cite this research output on Dimensions.

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study

Article in Frontiers in Oncology (April 2024)

Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule

Article in Future Oncology (March 2024)

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

Article in British Journal of Cancer (November 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.